EAM Investors LLC decreased its position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 7.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 92,899 shares of the biopharmaceutical company’s stock after selling 7,271 shares during the period. EAM Investors LLC owned approximately 0.36% of Esperion Therapeutics worth $4,656,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ESPR. Meditor Group Ltd grew its position in Esperion Therapeutics by 305.5% in the 3rd quarter. Meditor Group Ltd now owns 2,294,935 shares of the biopharmaceutical company’s stock worth $115,022,000 after purchasing an additional 1,728,935 shares during the last quarter. State Street Corp grew its position in Esperion Therapeutics by 264.6% in the 2nd quarter. State Street Corp now owns 1,506,514 shares of the biopharmaceutical company’s stock worth $69,721,000 after purchasing an additional 1,093,292 shares during the last quarter. Discovery Capital Management LLC CT grew its position in Esperion Therapeutics by 152.9% in the 2nd quarter. Discovery Capital Management LLC CT now owns 965,059 shares of the biopharmaceutical company’s stock worth $44,663,000 after purchasing an additional 583,529 shares during the last quarter. BNP Paribas Arbitrage SA grew its position in Esperion Therapeutics by 12,603.4% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 201,476 shares of the biopharmaceutical company’s stock worth $10,098,000 after purchasing an additional 199,890 shares during the last quarter. Finally, Pictet Asset Management Ltd. grew its position in Esperion Therapeutics by 112.3% in the 2nd quarter. Pictet Asset Management Ltd. now owns 272,881 shares of the biopharmaceutical company’s stock worth $8,738,000 after purchasing an additional 144,339 shares during the last quarter. Hedge funds and other institutional investors own 93.15% of the company’s stock.

Several research firms have recently issued reports on ESPR. Zacks Investment Research cut shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Deutsche Bank AG set a $64.00 price objective on shares of Esperion Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 9th. Northland Securities reiterated a “buy” rating and issued a $72.00 price objective on shares of Esperion Therapeutics in a report on Friday, November 10th. Stifel Nicolaus reiterated a “buy” rating and issued a $70.00 price objective (up from $60.00) on shares of Esperion Therapeutics in a report on Thursday, August 10th. Finally, Bank of America Corporation reiterated a “neutral” rating and issued a $60.00 price objective on shares of Esperion Therapeutics in a report on Friday, August 11th. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $58.92.

ILLEGAL ACTIVITY WARNING: This article was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/11/20/esperion-therapeutics-inc-espr-holdings-reduced-by-eam-investors-llc.html.

Esperion Therapeutics, Inc. (ESPR) traded up $3.23 during mid-day trading on Monday, reaching $52.42. 266,972 shares of the company traded hands, compared to its average volume of 1,047,633. Esperion Therapeutics, Inc. has a fifty-two week low of $10.30 and a fifty-two week high of $57.40.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing the consensus estimate of ($1.79) by ($0.07). During the same quarter last year, the business earned ($0.77) EPS. equities analysts predict that Esperion Therapeutics, Inc. will post -7.21 EPS for the current year.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Stock Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related stocks with our FREE daily email newsletter.